Cancer
Lung cancer in Wuhan
武汉 肺癌
5 hospitals in Wuhan
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Wuhan may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 176 papers led
- 147 papers led
- 105 papers led
- 74 papers ledNo open trial led
- 41 papers led
Lung cancer in every city Wuhan on the disease page, with the national map
open trials on lung cancer with a hospital in Wuhan
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Wuhan as lead sponsor or study site. 34 of them are led by a hospital in Wuhan. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06951646
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang
- RecruitingDurvalumab as Consolidation for Patients LS-SCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07055581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou
- RecruitingA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase
- Phase 2/Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07063745
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07227298
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Shanghai, Taizhou, Wuhan
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07253142
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou
- RecruitingA Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07264816
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07412262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07431827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Urumqi, Wuhan
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07476287
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07552467
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingSafety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07689643
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Phase
- Phase 2/Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07739199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Wuhan
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingA Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07824882
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingCAIX-targeted PET/CT in Solid Tumors
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07833085
Age 18 years to Not stated (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07912190
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06568939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Harbin, Linyi, Nanchang, Nanning, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Phase
- Phase 1/Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06772623
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06801834
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06839105
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT06868485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Shanghai, Tianjin, Wuhan
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06890598
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07005102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Wuhan
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingA Study of SKB518 in Patients With Lung Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07019675
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenzhen, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xiangyang, Zhengzhou
- RecruitingPredicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07059923
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07100080
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesFuzhou, Taiyuan, Wuhan
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingNanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07150663
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingPhase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07154706
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07155174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07174908
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07181473
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingIntraoperative Paravertebral Block and Postoperative Complications
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07211529
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingPrediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07388771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan
- RecruitingFL-261 Imaging for Cancer Diagnosis and Staging
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07510321
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingAdjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC
- Phase
- Not given
- Started
- 2025-07
- Posted
- Registry
- NCT07837739
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingLongitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07895277
Age 35 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingExploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT07947043
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingFirst Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT05745350
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingOmitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06020430
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingSingle-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06032052
Age 65 years to Not stated (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingPrimary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06037733
Age 18 years to 75 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- RecruitingPhase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06121505
Age 18 years to 75 years (registered criteria)
Led by West China Hospital; 4 listed hospitals as study sitesChengdu, Chongqing, Nanchong, Wuhan
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase
- Phase 3
- Started
- 2024-04
- Posted
- Registry
- NCT06312137
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Taizhou, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416410
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou
- RecruitingPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06422143
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06452277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen
- RecruitingDecoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach(Radiogenomics-Lung)
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06500312
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingDifferentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT06518655
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Chengdu, Foshan, Guangzhou, Shanghai, Wuhan
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06668103
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan
- RecruitingThe Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06692972
Age 18 years to Not stated (registered criteria)
Led by China-Japan Friendship Hospital; 1 listed hospital as study siteBeijing, Wuhan
- RecruitingA Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06768151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingClinical Application of PET Imaging Targeting MSLN in Malignant Tumors
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06843629
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingSymptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
- Phase
- Not given
- Started
- 2024-06
- Posted
- Registry
- NCT07131670
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT07463300
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 7 listed hospitals as study sitesChengdu, Hangzhou, Shenyang, Wuhan, Yangzhou
- RecruitingImproving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05830812
Age 20 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingIntegrin αvβ6-targeted PET in Malignant Tumors
- Phase
- Not given
- Started
- 2023-01
- Posted
- Registry
- NCT05835570
Age 18 years to 85 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06119581
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingClinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06199895
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingExploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
- Phase
- Not given
- Started
- 2023-08
- Posted
- Registry
- NCT06413212
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05334277
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Foshan, Guangzhou, Hangzhou, Jiangmen, Nanchang, Shenyang, Urumqi, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05498428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingCardiorespiratory Fitness After Lobectomy Versus Sublobar Resection
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT07841249
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04886804
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04557449
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingAPG-2449 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2019-05
- Posted
- Registry
- NCT03917043
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Wuhan
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingA Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07550842
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou
- Not yet recruitingA Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing)
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07609251
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingA Phase 2 Study of ABSK043 Combined With Osimertinib
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07710612
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan
- Not yet recruitingMulti-Omics Prediction of Radiation Lung Injury in Immunotherapy-Treated Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07742800
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingNeoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07807722
Age 18 years to 70 years (registered criteria)
Led by Hubei Cancer HospitalWuhan
- Not yet recruitingSafety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-09
- Posted
- Registry
- NCT07815951
Age 18 years to 75 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingAI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07829640
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07845916
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingA Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07865910
Age 18 days to 75 days (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesAnyang, Beijing, Chongqing, Guangzhou, Jinan, Nanning, Qingdao, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou, Zunyi
- Not yet recruitingUnion-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07882758
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingThe Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06768853
Age 18 years to 70 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingClinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06961188
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingClinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT06994078
Age 18 years to 65 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingPenfluridol for Relapsed/Refractory Small Cell Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206563
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingPrediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07287904
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- Not yet recruitingAdebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06236997
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer Hospital; 1 listed hospital as study siteWuhan, Zhengzhou
- Not yet recruitingClinical Study of 18F-Alfatide Injection PET/CT
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06416852
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingCryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2024-09
- Posted
- Registry
- NCT06580665
Age 18 years to Not stated (registered criteria)
Led by Shanghai Chest Hospital; 3 listed hospitals as study sitesNanchang, Shanghai, Wenzhou, Wuhan
- Not yet recruitingA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06594874
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Not yet recruitingMinimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT06709274
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Chengdu, Foshan, Guangzhou, Nanjing, Nantong, Shenzhen, Wuhan
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
- Enrolling by invitationEvaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07920822
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- Enrolling by invitationEfficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
- Phase
- Phase 3
- Started
- 2021-08
- Posted
- Registry
- NCT04762459
Age 18 years to 130 years (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- Enrolling by invitationThe Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06647836
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
- Enrolling by invitationPlasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT06730477
Age 18 years to 80 years (registered criteria)
Led by Union HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Wuhan
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Hubei University of Chinese Medicine湖北省中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Puren Hospital of Wuhan University of Science and Technology武汉市普仁医院 | 5 | none | none | none | none | none | none | none | none | 1 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Asia Heart Hospital武汉亚洲心脏病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Central Hospital, Tongji Medical College武汉市中心医院 | none | none | none | none | none | none | 19 | none | none | 2 | none | 3 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 15 | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Central Theater General Hospital中部战区总医院 | none | none | none | none | none | none | none | none | none | 2 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Child Health Hospital, Tongji Medical College湖北省妇幼保健院 | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | 2 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Geriatric Hospital, Wuhan University of Science武汉科技大学附属老年病医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guanggu Hospital武汉光谷医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hospital, Wuhan University of Science武汉科技大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Huangpi District People's Hospital黄陂区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hubei Cancer Hospital湖北省肿瘤医院 | 13 | 1 | 8 | 8 | 414 open | 6 | 457 open | none | none | none | none | 1 | 1 | 0 | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hubei Provincial Hospital湖北省人民医院 | none | none | 6 | none | none | none | none | none | none | 1 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Liyuan Hospital梨园医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| People's Hospital, Jianghan University湖北省第三人民医院 | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | |
| Renmin Hospital of Wuhan University武汉大学人民医院 | 13 | 122 open | 87 | 741 open | 74 | 29 | 68 | 61 | none | 5 | none | 31 | 2 | 10 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 18 | 4 | none | 1 | none | none | 1 | none | 3 | none | none | none | none | 2 | 0 | 2 | none | none | none | 1 | none | none | none | none | none | 2 | 2 | none | none | none | |
| Second Affiliated Hospital of Jianghan University武汉市第五医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianyou Hospital武汉科技大学附属天佑医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tongji Hospital华中科技大学同济医学院附属同济医院 | 8 | 102 open | 23823 open | 454 open | 1478 open | 666 open | 1165 open | 70 | 0 | 1 | 1 | 12 | 31 open | 8 | 0 | 193 open | 71 open | 8 | 201 open | 653 open | 0 | 4 | none | 6 | none | 187 open | 112 open | 178 open | 31 open | none | 21 open | 261 open | 14 | 7 | 2 | none | none | 14 | 1 | 111 open | none | 0 | none | 2 | 1 | 2 | 21 | 0 | 0 | 0 | 2 | none | none | 13 | 0 | 1 | 0 | 2 | none | none | none | |
| Union Hospital华中科技大学同济医学院附属协和医院 | 111 open | 81 open | 1446 open | 789 open | 17618 open | 706 open | 957 open | 612 open | 1 | 2 | 1 | 25 | 18 | 8 | 2 | 305 open | 32 open | 21 open | 8 | 468 open | none | 1 | none | none | 1 | 1 | 0 | 01 open | 2 | none | 7 | 411 open | 40 | 3 | 2 | 1 | none | 3 | none | 0 | none | none | none | none | 0 | none | 21 open | none | none | 1 | 3 | 0 | 1 | 8 | none | none | 0 | none | none | none | none | |
| Union Jiangnan Hospital, Huazhong University of Science武汉市江夏区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Union Wuhan Red Cross Hospital武汉市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| WISCO General Hospital华润武钢总医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuchang Eyegood Ophthalmic Hospital武汉武昌艾格眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuchang Hospital, Wuhan University of Science武汉市武昌医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Aier Eye Hospital武汉爱尔眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asia General Hospital武汉亚心总医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asia Heart Hospital武汉亚洲心脏病医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 15 | 26 | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asian Heart Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Children's Hospital武汉市儿童医院 | none | none | none | none | none | none | 3 | none | none | 1 | none | 1 | none | 1 | none | none | 1 | 0 | none | none | 1 | none | 1 | none | none | none | none | none | none | none | none | none | 8 | none | 0 | none | none | none | none | none | 1 | 0 | none | 1 | 1 | 1 | none | none | none | none | none | none | none | 0 | none | none | none | 1 | 1 | none | none | |
| Wuhan Fourth Hospital武汉市第四医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan General Hospital中国人民解放军广州军区武汉总医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Hanyang Hospital武汉市汉阳医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Hospital, Tongji Medical College武汉市中西医结合医院(武汉市第一医院) | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Jinyintan Hospital武汉市金银潭医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Third Hospital武汉市第三医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Tongji Reproductive Medicine Hospital武汉同济生殖医学专科医院 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan University Hospital武汉大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Xinzhou District People's Hospital武汉市新洲区人民医院 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongnan Hospital of Wuhan University武汉大学中南医院 | 11 | 2 | 97 | 292 open | 1054 open | 21 | 814 open | 721 open | none | 2 | none | 19 | 1 | 6 | 1 | 123 open | none | 2 | none | 141 open | none | none | none | none | 2 | none | none | none | 13 | none | none | 12 | 5 | 2 | 2 | 1 | none | 6 | 0 | 1 | none | none | none | 1 | 2 | none | 1 | none | none | none | 0 | 1 | none | none | none | none | 1 | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Wuhan.
- Nasopharyngeal carcinoma 13
- Oesophageal squamous cell carcinoma 122 open
- Hepatocellular carcinoma 87
- Stomach cancer 741 open
- Lung cancer 74
- Pancreatic cancer 29
- Breast cancer 68
- Glioma 61
- Retinoblastoma 5
- Osteosarcoma 31
- Gastrointestinal stromal tumour 2
- Neuroblastoma 10
- Ewing sarcoma 1
- Myasthenia gravis 0
- Coronary heart disease 18
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 3
- Behçet disease 2
- Alport syndrome 0
- IgA nephropathy 2
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 2
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 102 open
- Hepatocellular carcinoma 23823 open
- Stomach cancer 454 open
- Lung cancer 1478 open
- Pancreatic cancer 666 open
- Breast cancer 1165 open
- Glioma 70
- Hepatoblastoma 0
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 12
- Gastrointestinal stromal tumour 31 open
- Neuroblastoma 8
- Ewing sarcoma 0
- Multiple myeloma 193 open
- B-cell acute lymphoblastic leukaemia 71 open
- Aplastic anaemia 8
- Haemophagocytic lymphohistiocytosis 201 open
- Lymphoma 653 open
- Beta thalassaemia 0
- Haemophilia A 4
- Thrombotic thrombocytopenic purpura 6
- Neuromyelitis optica spectrum disorder 187 open
- IgG4-related disease 112 open
- Myasthenia gravis 178 open
- Moyamoya disease 31 open
- Biliary atresia 21 open
- Coronary heart disease 261 open
- Congenital heart disease 14
- Scoliosis 7
- Anti-NMDA receptor encephalitis 2
- Idiopathic pulmonary fibrosis 14
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 111 open
- Fabry disease 0
- Duchenne muscular dystrophy 2
- Behçet disease 1
- Alport syndrome 2
- IgA nephropathy 21
- Gaucher disease 0
- Niemann–Pick disease type C 0
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 2
- Hirschsprung disease 13
- Inherited epidermolysis bullosa 0
- Hereditary angioedema 1
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 111 open
- Oesophageal squamous cell carcinoma 81 open
- Hepatocellular carcinoma 1446 open
- Stomach cancer 789 open
- Lung cancer 17618 open
- Pancreatic cancer 706 open
- Breast cancer 957 open
- Glioma 612 open
- Hepatoblastoma 1
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 25
- Gastrointestinal stromal tumour 18
- Neuroblastoma 8
- Ewing sarcoma 2
- Multiple myeloma 305 open
- B-cell acute lymphoblastic leukaemia 32 open
- Aplastic anaemia 21 open
- Haemophagocytic lymphohistiocytosis 8
- Lymphoma 468 open
- Haemophilia A 1
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 1
- IgG4-related disease 0
- Myasthenia gravis 01 open
- Moyamoya disease 2
- Biliary atresia 7
- Coronary heart disease 411 open
- Congenital heart disease 40
- Scoliosis 3
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 3
- Amyotrophic lateral sclerosis 0
- Behçet disease 0
- IgA nephropathy 21 open
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 8
- Familial adenomatous polyposis 0
- Breast cancer 3
- Retinoblastoma 1
- Osteosarcoma 1
- Neuroblastoma 1
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 0
- Beta thalassaemia 1
- Atypical haemolytic uraemic syndrome 1
- Congenital heart disease 8
- Anti-NMDA receptor encephalitis 0
- Spinal muscular atrophy 1
- Fabry disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- Alport syndrome 1
- Hirschsprung disease 0
- Leber hereditary optic neuropathy 1
- Majeed syndrome 1
- Nasopharyngeal carcinoma 11
- Oesophageal squamous cell carcinoma 2
- Hepatocellular carcinoma 97
- Stomach cancer 292 open
- Lung cancer 1054 open
- Pancreatic cancer 21
- Breast cancer 814 open
- Glioma 721 open
- Retinoblastoma 2
- Osteosarcoma 19
- Gastrointestinal stromal tumour 1
- Neuroblastoma 6
- Ewing sarcoma 1
- Multiple myeloma 123 open
- Aplastic anaemia 2
- Lymphoma 141 open
- Fanconi anaemia 2
- Moyamoya disease 13
- Coronary heart disease 12
- Congenital heart disease 5
- Scoliosis 2
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 6
- Lymphangioleiomyomatosis 0
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Behçet disease 2
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Wuhan on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.